Assertio Holdings, Inc.
https://www.assertiotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Assertio Holdings, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Five Clinical Trial Misses Of 2022
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
UPDATED: JPM 2023: Baxter, Medtronic Pursue Simplification As Path To Growth
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Depomed, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice